$0.83
15.62% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US82024L1035
Symbol
STTK
Sector
Industry

Shattuck Labs Inc Stock price

$0.98
-0.24 19.38% 1M
-0.27 21.31% 6M
-0.23 18.71% YTD
-7.73 88.71% 1Y
-3.32 77.13% 3Y
-16.02 94.21% 5Y
-16.02 94.21% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.14 16.28%
ISIN
US82024L1035
Symbol
STTK
Sector
Industry

Key metrics

Market capitalization $47.11m
Enterprise Value $-22.47m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.37
EV/Sales (TTM) EV/Sales -3.93
P/S ratio (TTM) P/S ratio 8.24
P/B ratio (TTM) P/B ratio 0.59
Revenue growth (TTM) Revenue growth 245.26%
Revenue (TTM) Revenue $5.72m
EBIT (operating result TTM) EBIT $-80.49m
Free Cash Flow (TTM) Free Cash Flow $-60.57m
Cash position $72.99m
EPS (TTM) EPS $-1.49
Short interest 5.27%
Show more

Is Shattuck Labs Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Shattuck Labs Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Shattuck Labs Inc forecast:

2x Buy
50%
2x Hold
50%

Analyst Opinions

4 Analysts have issued a Shattuck Labs Inc forecast:

Buy
50%
Hold
50%

Financial data from Shattuck Labs Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
5.72 5.72
245% 245%
100%
- Direct Costs 3.83 3.83
9% 9%
67%
1.89 1.89
174% 174%
33%
- Selling and Administrative Expenses 11 11
5% 5%
200%
- Research and Development Expense 67 67
10% 10%
1,174%
-77 -77
13% 13%
-1,340%
- Depreciation and Amortization 3.83 3.83
9% 9%
67%
EBIT (Operating Income) EBIT -80 -80
12% 12%
-1,407%
Net Profit -75 -75
14% 14%
-1,318%

In millions USD.

Don't miss a Thing! We will send you all news about Shattuck Labs Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Shattuck Labs Inc Stock News

Neutral
GlobeNewsWire
about 20 hours ago
AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one...
Neutral
GlobeNewsWire
7 days ago
– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable safety profile, full receptor occupancy, lack of DR3 agonism –
Neutral
GlobeNewsWire
about one month ago
– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxicology study –  – SL-325 receptor occupancy (RO) and pharmacokinetic (PK) profile observed suggestive of extended dosing intervals; IND filing expected in the third quarter of 2025 –  AUSTIN, TX & D...
More Shattuck Labs Inc News

Company Profile

Shattuck Labs, Inc. engages in the research and development of Agonist Redirected Checkpoint (ARC) platform. It develops a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and autoimmune diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.

Head office United States
CEO Taylor Schreiber
Employees 44
Founded 2016
Website www.shattucklabs.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today